Concerta

Lei Lei, MD · FDA-approved active Small molecule Quality 16/100

Concerta is a Small molecule drug developed by Lei Lei, MD. It is currently FDA-approved for Attention deficit hyperactivity disorder, Narcolepsy. Also known as: Methylphenidate Hydrochloride Extended-Release Tablets, methylphenidate hydrochloride, Methylphenidate, Methylphenidate HCL.

Concerta is a central nervous system stimulant used in the treatment of attention deficit hyperactivity disorder (ADHD). It works by inhibiting the sodium-dependent dopamine transporter, a mechanism that is consistent with its classification as a small molecule inhibitor.

At a glance

Generic name	Concerta
Also known as	Methylphenidate Hydrochloride Extended-Release Tablets, methylphenidate hydrochloride, Methylphenidate, Methylphenidate HCL, Methylphenidate hydrochloride (HCl)
Sponsor	Lei Lei, MD
Target	Alpha-2A adrenergic receptor, Alpha-2B adrenergic receptor, Alpha-2C adrenergic receptor
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved

Approved indications

• Attention deficit hyperactivity disorder
• Narcolepsy

Common side effects

• Anxiety
• Irritability
• Increased blood pressure
• Nervousness
• Insomnia
• Decreased appetite
• Tic

Serious adverse events

• Priapism
• Peripheral Vasculopathy, including Raynaud's Phenomenon
• Long-Term Suppression of Growth in Pediatric Patients
• Acute Angle Closure Glaucoma
• Increased Intraocular Pressure and Glaucoma
• Gastrointestinal Obstruction
• Hypersensitivity Reactions
• Abuse, Misuse, and Addiction
• Psychiatric Adverse Reactions
• Risks to Patients with Serious Cardiac Disease

Key clinical trials

• Orexin s Role in the Neurobiology of Substance Use Disorder (NA)
• The Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome (PHASE4)
• Benefits of ADHD Treatment in Detained People (PHASE3)
• Methylphenidate to Address Attention and Executive Deficits Among Children With Sickle Cell Disease (PHASE1)
• A Trial to Assess How Centanafadine Interacts With Stimulants in the Body (PHASE1)
• Comorbidity Between Attention Deficit Hyperactivity Disorder and Fibromyalgia (NA)
• The Effect Of Methylphenıdate Treatment On Neuroınflammatıon Levels In Chıldren Wıth Attentıon Defıcıt Hyperactıvıty Dısorder
• Multimodal Therapy for the Treatment of Fatigue in Patients With Prostate Cancer Receiving Radiotherapy With Androgen Deprivation Therapy (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Concerta CI brief — competitive landscape report
• Concerta updates RSS · CI watch RSS
• Lei Lei, MD portfolio CI

Frequently asked questions about Concerta

What is Concerta?

Concerta is a Small molecule drug developed by Lei Lei, MD, indicated for Attention deficit hyperactivity disorder, Narcolepsy.

What is Concerta used for?

Concerta is indicated for Attention deficit hyperactivity disorder, Narcolepsy.

Who makes Concerta?

Concerta is developed and marketed by Lei Lei, MD (see full Lei Lei, MD pipeline at /company/lei-lei-md).

Is Concerta also known as anything else?

Concerta is also known as Methylphenidate Hydrochloride Extended-Release Tablets, methylphenidate hydrochloride, Methylphenidate, Methylphenidate HCL, Methylphenidate hydrochloride (HCl).

What development phase is Concerta in?

Concerta is FDA-approved (marketed).

What are the side effects of Concerta?

Common side effects of Concerta include Anxiety, Irritability, Increased blood pressure, Nervousness, Insomnia, Decreased appetite. Serious adverse events: Priapism, Peripheral Vasculopathy, including Raynaud's Phenomenon, Long-Term Suppression of Growth in Pediatric Patients, Acute Angle Closure Glaucoma.

What does Concerta target?

Concerta targets Alpha-2A adrenergic receptor, Alpha-2B adrenergic receptor, Alpha-2C adrenergic receptor.

Related

• Target: All drugs targeting Alpha-2A adrenergic receptor, Alpha-2B adrenergic receptor, Alpha-2C adrenergic receptor
• Manufacturer: Lei Lei, MD — full pipeline
• Therapeutic area: All drugs in Other
• Indication: Drugs for Attention deficit hyperactivity disorder
• Indication: Drugs for Narcolepsy
• Also known as: Methylphenidate Hydrochloride Extended-Release Tablets, methylphenidate hydrochloride, Methylphenidate, Methylphenidate HCL, Methylphenidate hydrochloride (HCl)